
## Wang Lin

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9914587/publications.pdf Version: 2024-02-01



WANGLIN

#	Article	IF	CITATIONS
1	A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors. Acta Pharmacologica Sinica, 2022, 43, 483-493.	2.8	43
2	Probing the Allosteric Inhibition Mechanism of a Spike Protein Using Molecular Dynamics Simulations and Active Compound Identifications. Journal of Medicinal Chemistry, 2022, 65, 2827-2835.	2.9	15
3	Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. Acta Pharmacologica Sinica, 2022, 43, 788-796.	2.8	40
4	Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth. Cell Chemical Biology, 2022, 29, 373-385.e6.	2.5	31
5	Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2. Journal of Natural Products, 2022, 85, 327-336.	1.5	13
6	Crystal Structures of Wolbachia CidA and CidB Reveal Determinants of Bacteria-induced Cytoplasmic Incompatibility and Rescue. Nature Communications, 2022, 13, 1608.	5.8	15
7	Recent advances in predicting protein–protein interactions with the aid of artificial intelligence algorithms. Current Opinion in Structural Biology, 2022, 73, 102344.	2.6	24
8	Identification of Potential Binding Sites of Sialic Acids on the RBD Domain of SARS-CoV-2 Spike Protein. Frontiers in Chemistry, 2021, 9, 659764.	1.8	21
9	CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia, 2021, 23, 1147-1165.	2.3	15
10	The structural study of mutation-induced inactivation of human muscarinic receptor M4. IUCrJ, 2020, 7, 294-305.	1.0	9